NCT06793449View on ClinicalTrials.gov

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

anti-BCMA CAR-T

Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.

BIOLOGICAL

ASCT

Autologous stem cell infusion

Trial Locations (1)

Unknown

RECRUITING

Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER